2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 989

Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Abstract Number: 990

Higher Omega-6 to Omega-3 Fatty Acid Ratio Is Associated with Increased Odds of Inflammatory Arthritis in a Health Fair Population Positive for Anti-Citrullinated Protein Antibodies (ACPA)
Abstract Number: 991

Publication Timeliness of the Randomized Controlled Trials of Drug Therapy for Inflammatory Arthritis
Abstract Number: 992

The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Abstract Number: 993

Increase in Prevalence of Psoriasis Arthritis over Time: Analysis of Claims Data from 65 Million People in Germany from 2009 to 2012
Abstract Number: 994

Increasing Population Burden of Psoriatic Disease in Ontario, Canada – a Longitudinal Cohort Study
Abstract Number: 995

The Epidemiology of Psoriatic Arthritis in Israel – a Population-Based Study
Abstract Number: 996

Accuracy of Canadian Administrative Health Data in Identifying Patients with Psoriasis and Psoriatic Arthritis Using Primary Care Medical Records As the Reference Standard
Abstract Number: 997

Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Abstract Number: 998

Mental Health in Patients with Axial Spondyloarthritis: Increasing Our Understanding of the Disease. Results from the Spanish Atlas
Abstract Number: 999

Association between Smoking with Spinal Level of Stiffness and Functional Limitation in Patients with Axial Spondyloarthritis: Results from the Spanish Atlas
Abstract Number: 1000

Use of Mutual Information Theory in Development and Refinement of a Predictive Model for Early Identification of Ankylosing Spondylitis
Abstract Number: 1001

Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy
Abstract Number: 1002

Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)
Abstract Number: 1003

Hair Treatments and the Risk of Systemic Lupus Erythematosus: the Michigan Lupus Epidemiology & Surveillance (MILES) Program

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].